retatrutide obesity trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Triple hormone receptor agonist retatrutide

The program also integrates seamlessly with our other wellness services including Hormone Replacement Therapy, Peptide Therapy, and IV Vitamin Therapy for patients whose weight challenges have additional hormonal or nutritional contributing factors

The first generation of weight loss drugs focused on stimulant effects or blocking fat absorption, approaches that produced modest results with significant side effects and safety concerns

Velasquez M, OSullivan C, Brockett R, Mikels-Vigdal A, Mikaelian I, Smith V, et al

A search of their home yielded two kilograms of a blue bonding agent and more than 1,000 Xanax pills made with fentanyl